Sirtex gets hammered on failed cancer study

Shares of Australia's Sirtex Medical were slammed hard after the biotech reported that its liver cancer therapy failed a closely watched clinical study. The biotech had been hoping to offer data proving that its SIR-Spheres treatment should be used as a frontline treatment for cancer rather than in last-ditch efforts. But investigators tried to salvage something with data indicating an effect on tumors in the liver. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.